The Future of Pharma

SWISS MADE
Capital increase 2022
Become a shareholder of MediCrops and participate in the capital increase. Order the investor documents now.

Harnessing the potential of medicinal cannabis

Leading manufacturer

MediCrops, based in Switzerland, is one of, if not the leading research and development company.  The premium quality medicinal cannabis products are made for the European market, with a focus on the German-speaking region.

Medicinal cannabis and MediCrops

Medicinal cannabis market

Cannabis is cultivated and exported worldwide. Cultivation in Europe often takes place in so-called indoor facilities, especially in Germany, the Netherlands and Italy.

The responsible Committee of the Council of States, i.e. the body that represents the cantons in the Swiss parliament, has given the green light by a clear majority for cultivation, production, trade and consumption to be newly regulated. Accordingly, the Narcotics Act will be amended to facilitate the distribution of cannabis for medicinal purposes and to allow its export.

This has created the basis for a regulated and legal cannabis market in Switzerland with great growth potential.

One of the most promising markets of the future

Largest growth market globally:
0

BILLIONS OF US DOLLARS
(UP TO 2028)

Market growth
Global:
0 %

(CAGR 2021–2028)

Investment requirement
MediCrops:
0

MILLIONS OF SWISS FRANCS (UP TO 2026)

Medium
Rating Multiple:
0 x

EBITDA (until 2028)

Market potential in
Europe:
0

BILLIONS OF US DOLLARS
(UP TO 2028)

Rapid growth
Europe:
0 %

(CAGR 2021–2028)

Volume acceptance
Production:
0

TONS OF THC-CONTAINING PRODUCTS (UNTIL 2028)

High
EBITDA margins:
0

(Until 2028)

Be part of the success

Profitable investment

Building on its positioning as a high-quality and fully integrated producer of medicinal cannabis, MediCrops is expected to benefit from the rapidly growing markets in Germany, Austria and Switzerland and gain a significant market share.

Milestones

0000
0000
0000